Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Harmony Biosciences Holdings (HRMY) Equity Average (2019 - 2025)

Harmony Biosciences Holdings' Equity Average history spans 7 years, with the latest figure at $852.7 million for Q4 2025.

  • For Q4 2025, Equity Average rose 35.78% year-over-year to $852.7 million; the TTM value through Dec 2025 reached $852.7 million, up 35.78%, while the annual FY2025 figure was $764.7 million, 35.81% up from the prior year.
  • Equity Average for Q4 2025 was $852.7 million at Harmony Biosciences Holdings, up from $804.1 million in the prior quarter.
  • Across five years, Equity Average topped out at $852.7 million in Q4 2025 and bottomed at $102.5 million in Q1 2021.
  • The 5-year median for Equity Average is $469.1 million (2023), against an average of $439.0 million.
  • The largest annual shift saw Equity Average surged 171.65% in 2021 before it rose 13.55% in 2024.
  • A 5-year view of Equity Average shows it stood at $169.3 million in 2021, then soared by 120.58% to $373.4 million in 2022, then grew by 27.0% to $474.2 million in 2023, then surged by 32.44% to $628.0 million in 2024, then soared by 35.78% to $852.7 million in 2025.
  • Per Business Quant, the three most recent readings for HRMY's Equity Average are $852.7 million (Q4 2025), $804.1 million (Q3 2025), and $746.8 million (Q2 2025).